Why did Gilead's GAAP EPS swing to a loss in Q1 2024?

The loss was driven by non-cash and one-time charges rather than operating weakness. A $3.9 billion acquired IPR&D charge from the CymaBay acquisition (about $3.14 per share) and a $2.4 billion IPR&D impairment on assets acquired from Immunomedics in 2020 (about $1.46 per share) pushed GAAP diluted EPS to $(3.34). Excluding these items, non-GAAP diluted EPS was $(1.32), and the acquisition charge is the main driver of that non-GAAP decline as well.

Did Gilead change its full-year 2024 sales outlook?

No. Product sales guidance remained unchanged at $27.1–$27.5 billion, and product sales excluding Veklury remained at $25.8–$26.2 billion. The cut was to EPS guidance, with GAAP diluted EPS now $0.10–$0.50 (previously $5.15–$5.55) and non-GAAP diluted EPS $3.45–$3.85 (previously $6.85–$7.25), reflecting the acquisition and impairment charges and their tax effects.

How healthy is the underlying business excluding the one-time charges?

The core business showed solid growth. Product sales excluding Veklury rose 6% to $6.1 billion, with Biktarvy up 10%, Oncology up 18%, and Liver Disease up 9%. Non-GAAP product gross margin was 85.4%, versus 86.2% a year earlier, mainly due to product mix. Non-GAAP operating expenses were roughly flat year-over-year. Descovy and Veklury were the main decliners.

What does the CymaBay acquisition add, and what is the near-term catalyst?

The CymaBay acquisition, closed March 22, 2024 for $4.3 billion in total equity value ($3.9 billion net cash paid), added seladelpar, an investigational oral PPARδ agonist for primary biliary cholangitis with orphan drug designation in the U.S. and Europe. The FDA accepted the New Drug Application for priority review, with a PDUFA target action date of August 14, 2024. Approval would be a key milestone for the Liver Disease franchise, though the outcome is not assured.

How is Gilead's balance sheet and capital return affected?

Cash and marketable debt securities fell to $4.7 billion from $8.4 billion at year-end 2023, largely due to the CymaBay payment. Gilead still generated $2.2 billion in operating cash flow and $2.1 billion in free cash flow in the quarter, paid $990 million in dividends, and repurchased $400 million of stock. Total stockholders' equity fell to $17.5 billion from $22.7 billion, reflecting the GAAP loss, and the Board declared a $0.77 quarterly dividend for Q2 2024.

GILD 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed April 25, 2024. Cited figures are marked; the original filing is the authoritative source.

Gilead Sciences reported first quarter 2024 results on April 25, 2024, showing underlying commercial strength but a sharply lower GAAP profit picture driven by a one-time acquisition charge.

Total revenue rose 5% to $6.7 billion^a, and product sales excluding Veklury grew 6% to $6.1 billion, led by Biktarvy (up 10% to $2.9 billion), Oncology (up 18% to $789 million, with Trodelvy up 39%), and Liver Disease (up 9% to $737 million). Growth in the base business was offset by a $4.1 billion acquired IPR&D charge, primarily the $3.9 billion charge from the CymaBay Therapeutics acquisition, plus a $2.4 billion IPR&D impairment tied to older Immunomedics assets. As a result, GAAP diluted EPS was $(3.34) versus $0.80 a year earlier, while non-GAAP diluted EPS was $(1.32) versus $1.37.

The company materially cut its full-year 2024 GAAP diluted EPS guidance to $0.10^b–$0.50 from $5.15–$5.55, and non-GAAP diluted EPS guidance to $3.45–$3.85 from $6.85–$7.25. Management left product sales guidance unchanged at $27.1–$27.5 billion, so the revision reflects the non-cash and acquisition-related charges rather than a deterioration in expected sales.

Cash fell to $4.7 billion^c from $8.4 billion at year-end 2023 following the CymaBay deal, though operating cash flow of $2.2 billion and a $0.77 quarterly dividend were maintained. The key near-term catalyst highlighted is the FDA decision on seladelpar for primary biliary cholangitis, with a PDUFA date of August 14, 2024.

02—Key points

Key Highlights

Total revenue rose 5% year-over-year to $6.7 billion; product sales excluding Veklury grew 6% to $6.1 billion, led by HIV, Oncology and Liver Disease.
GAAP diluted EPS was $(3.34) versus $0.80 a year ago, driven by a $3.9 billion ($3.14/share) acquired IPR&D charge from CymaBay and a $2.4 billion ($1.46/share) IPR&D impairment on Immunomedics assets.
Non-GAAP diluted EPS was $(1.32) versus $1.37 a year ago, reflecting the CymaBay charge; non-GAAP results exclude the impairment and acquisition-related items.
FY2024 GAAP diluted EPS guidance was cut to $0.10–$0.50 from $5.15–$5.55; non-GAAP guidance was lowered to $3.45–$3.85 from $6.85–$7.25, while product sales guidance ($27.1–$27.5 billion) was unchanged.
Biktarvy sales grew 10% to $2.9 billion and Trodelvy grew 39% to $309 million, while Descovy declined 5% due to channel mix and Veklury fell 3%.
Cash, cash equivalents and marketable securities declined to $4.7 billion from $8.4 billion at December 31, 2023, following the $3.9 billion net cash paid for CymaBay; operating cash flow was $2.2 billion.
Seladelpar (CymaBay asset for PBC) has an FDA PDUFA target action date of August 14, 2024, a key near-term catalyst; the quarterly dividend was declared at $0.77 per share.

03—Questions

Frequently Asked Questions

Why did Gilead's GAAP EPS swing to a loss in Q1 2024?
The loss was driven by non-cash and one-time charges rather than operating weakness. A $3.9 billion acquired IPR&D charge from the CymaBay acquisition (about $3.14 per share) and a $2.4 billion IPR&D impairment on assets acquired from Immunomedics in 2020 (about $1.46 per share) pushed GAAP diluted EPS to $(3.34). Excluding these items, non-GAAP diluted EPS was $(1.32), and the acquisition charge is the main driver of that non-GAAP decline as well.
Did Gilead change its full-year 2024 sales outlook?
No. Product sales guidance remained unchanged at $27.1–$27.5 billion, and product sales excluding Veklury remained at $25.8–$26.2 billion. The cut was to EPS guidance, with GAAP diluted EPS now $0.10–$0.50 (previously $5.15–$5.55) and non-GAAP diluted EPS $3.45–$3.85 (previously $6.85–$7.25), reflecting the acquisition and impairment charges and their tax effects.
How healthy is the underlying business excluding the one-time charges?
The core business showed solid growth. Product sales excluding Veklury rose 6% to $6.1 billion, with Biktarvy up 10%, Oncology up 18%, and Liver Disease up 9%. Non-GAAP product gross margin was 85.4%, versus 86.2% a year earlier, mainly due to product mix. Non-GAAP operating expenses were roughly flat year-over-year. Descovy and Veklury were the main decliners.
What does the CymaBay acquisition add, and what is the near-term catalyst?
The CymaBay acquisition, closed March 22, 2024 for $4.3 billion in total equity value ($3.9 billion net cash paid), added seladelpar, an investigational oral PPARδ agonist for primary biliary cholangitis with orphan drug designation in the U.S. and Europe. The FDA accepted the New Drug Application for priority review, with a PDUFA target action date of August 14, 2024. Approval would be a key milestone for the Liver Disease franchise, though the outcome is not assured.
How is Gilead's balance sheet and capital return affected?
Cash and marketable debt securities fell to $4.7 billion from $8.4 billion at year-end 2023, largely due to the CymaBay payment. Gilead still generated $2.2 billion in operating cash flow and $2.1 billion in free cash flow in the quarter, paid $990 million in dividends, and repurchased $400 million of stock. Total stockholders' equity fell to $17.5 billion from $22.7 billion, reflecting the GAAP loss, and the Board declared a $0.77 quarterly dividend for Q2 2024.

04—Continue

← View all 8-K filings